Abstract 367P
Background
MET amplification is a rare genetic mutation which can be treated with small-molecule inhibitor-crizotinib. Based on the detection of next-generation sequencing, the molecular characteristics and the efficacy of crizotinib among different subsets of MET amplification in lung cancer patients is poorly understood.
Methods
From January 2018 to April 2019, patients with MET amplification detected by next-generation sequencing were retrospectively collected and the efficacy of crizotinib among different subsets of patients were analyzed.
Results
In our study, 4.16% (112/2694) patients were found to have MET amplification and only 19 patients treated with monotherapy crizotinib. Among the 112 MET amplification patients, primary (with or without other mutation) MET amplification accounted for 3.27% (82/2507) and 16.04% (30/187) re-biopsy patients were found to have acquired MET amplification after the failed treatment of EGFR-TKI. The frequency of MET amplification combined with EGFR 21L858R was slightly higher than that of MET amplification combined with EGFR 19 del (primary or acquired). Primary MET amplification can occur simultaneously with EGFR 20ins or ALK rearrangement. In survival analysis, the median PFS of 10 patients with copy number greater than 4 (CN > 4) seems longer than the nine patients with copy number less than or equal to 4 (CN ≤ 4) (4.7 months vs 2.7 months) and the two curves were separate, but failed to get a statistical significance (p = 0.085). No significant difference has been discovered between the median PFS of primary (4.04 months; 95%CI: 0.33-7.74 months) and acquired (2.99 months; 95% CI: 2.51-3.47 months; P = 0.382) MET amplification.
Conclusions
4.16% lung cancer patients were found to have MET amplification based on the detection of NGS. MET amplification patients treated with crizotinib with copy number greater than 4 (CN > 4) seem have longer PFS. No obvious survival difference has been discovered between primary and acquired MET amplification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract